Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide-Reference-Cited by-同舟云学术

Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

Published:2016-01-13 Issue:9 Volume:57 Page:2228-2231
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Rifkin Robert M.,Abonour Rafat,Shah Jatin J.,Mehta Jayesh,Narang Mohit,Terebelo Howard,Gasparetto Cristina,Toomey Kathleen,Hardin James W.,Lu Jane Jie,Kenvin Laurie,Srinivasan Shankar,Knight Robert,Nagarwala Yasir,Durie Brian G. M.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://tandfonline.com/doi/pdf/10.3109/10428194.2015.1132419

Reference13 articles.

1. Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival

2. Update on second primary malignancies in multiple myeloma: a focused review

3. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry;Clinical Lymphoma Myeloma and Leukemia;2024-06

2. Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients;Cureus;2021-07-13

3. Future Directions in Maintenance Therapy in Multiple Myeloma;Journal of Clinical Medicine;2021-05-24

4. Second primary malignancies in multiple myeloma: A review;Blood Reviews;2021-03

5. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis;Journal of Geriatric Oncology;2021-03